drugset / Trial / NCT00410371

Study to Compare Two Formulations of Lamotrigine in Healthy Subjects

NCT00410371

Phase 1 Completed 96 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This study intends to compare the pharmacokinetic characteristics, safety and tolerability of two formulations of lamotrigine in healthy male and female volunteers

Timeline

Start
2006-12-28
Primary completion
2007-01-25
Completion
2007-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule 25 mg Oral
Subject Lamotrigine Small molecule 200 mg Oral

Indications